You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma
|
|---|---|
| Published in |
Clinical Cancer Research, March 2004
|
| DOI | 10.1158/1078-0432.ccr-1103-3 |
| Pubmed ID | |
| Authors |
John M. Kirkwood, Judith Manola, Joseph Ibrahim, Vernon Sondak, Marc S. Ernstoff, Uma Rao |
| Abstract |
Nearly 2000 patients with stage IIB and III melanoma have participated in four multicenter, randomized trials, conducted by the Eastern Cooperative Oncology Group and the Intergroup, investigating adjuvant high-dose IFN-alpha 2b therapy. The objectives of this study were to update the analyses of each individual trial and to analyze prognostic factors and treatment effects based on pooled data. Survival and disease status were updated to April 2001. Analysis of prognostic factors using optimized statistical models was based on data from patients in E1684, E1690, E1694, and E2696. Analysis of treatment effects versus observation (Obs) was based on data from 713 patients randomized to high-dose IFN-alpha 2b (HDI) or Obs in Trials E1684 and E1690. Updated analysis of E1684, E1690, and E1694 confirmed their original conclusions, now at median follow-up intervals of 2.1-12.6 years. Based on two-sided univariate log-rank analysis of pooled data from E1684 and E1690 (median follow-up, 7.2 years), relapse-free survival (RFS)-but not overall survival (OS)-was significantly prolonged (two-sided log-rank P value = 0.006) for patients treated with HDI versus Obs. Among all patients, prognostic factors that significantly negatively impacted RFS and OS included ulceration, recurrent disease at entry, enrollment in E1684, and age > 49 years. Multivariate statistical models adjusting for these factors confirmed the statistically significant RFS benefit of HDI versus Obs but did not demonstrate a significant OS benefit in the pooled populations. In patients with high-risk resected melanoma, HDI is effective adjuvant therapy with strong evidence for improved RFS and evidence for moderate improvement in OS based on two prospective randomized studies but not the pooled analysis. Analyses of predictors of relapse and response are now needed to improve the therapeutic value of this modality. |
Mendeley readers
The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Germany | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 102 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 27 | 26% |
| Other | 22 | 21% |
| Student > Doctoral Student | 12 | 11% |
| Student > Ph. D. Student | 9 | 9% |
| Student > Bachelor | 7 | 7% |
| Other | 17 | 16% |
| Unknown | 11 | 10% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 63 | 60% |
| Agricultural and Biological Sciences | 17 | 16% |
| Biochemistry, Genetics and Molecular Biology | 4 | 4% |
| Business, Management and Accounting | 2 | 2% |
| Psychology | 2 | 2% |
| Other | 3 | 3% |
| Unknown | 14 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 January 2024.
All research outputs
#1,927,804
of 24,927,532 outputs
Outputs from Clinical Cancer Research
#1,501
of 13,133 outputs
Outputs of similar age
#2,530
of 62,560 outputs
Outputs of similar age from Clinical Cancer Research
#3
of 175 outputs
Altmetric has tracked 24,927,532 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,133 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 62,560 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 175 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.